natgillin/translations-raw huggingface dataset:
Step #9. 
Korak 9.
Step #6. 
Korak 6.
Stage 1 chlorhexidine coating 
Faza 1 klorheksidinski premaz
The other ingredients are Sumatra benzoin and Ethanol 
Pomožni snovi sta sumatra benzoin in etanol.
Driving and using machines Prevora has not been shown to affect driving. 
Prevora se ni pokazala, da bi imela vpliv na vožnjo.
Do not eat hard foods (e.g. meat, apples) for at least 4 hours after treatment. 
Ne jejte trde hrane (npr. meso, jabolka) najmanj štiri ure po obravnavi.
Step #7. 
Korak 7.
No controlled studies have been carried out to ascertain if there are any adverse reactions when Prevora 100 mg/ml Dental Solution is applied to the dentition of women of childbearing potential, or to the dentition of expectant or breast feeding mothers. 
Kontroliranih študi, ki bi pokazale neželene učinke zdravila Prevora 100 mg/ml Dental Solution pri dentalni uporabi na zobovju žensk v rodni dobi oziroma nosečnic ali doječih mater, niso izvedli.
A clear, slightly brownish solution with a characteristic odour, free of visible particulate matter. 
Prozorna, rahlo rjavkasta raztopina, z značilnim vonjem, brez vidnih delcev.
• Do not chew gum for at least 24 hours. 
• naj ne žvečite žvečilnega gumija vsaj 24 ur.
Step #3. 
Korak 3.
The cotton pellet or brush is dipped into the Prevora 100 mg/ml Dental solution and thereafter is applied to the tooth surfaces (Figure 1). 
Bambažno peleto ali čopič se namoči v Prevora 100 mg/ml Dental Solution in raztopino nato nanese na zobno površino.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml of Prevora Dental Solution (Stage 1 chlorhexidine coating) contains chlorhexidine diacetate 100mg 
KAKOVOSTNA IN KOLIČINSKA SESTAVA 1 ml zdravila Prevora dentalna raztopina (faza 1 klorheksidinskega premaza) vsebuje 100 mg klorheksidin diacetata.
Step #4. 
Korak 4.
Do not brush your teeth for 24 hours after this treatment. 
Ne ščetkajte zob najmanj 24 ur po obravnavi.
HOW YOU ARE TREATED WITH PREVORA 
KAKO POTEKA ZDRAVLJENJE S PREVORA
Then you resume flossing daily. 
Nato nitkajte na dnevni osnovi.
100 mg/ml Dental solution, chlorhexidine diacetate Stage 2 Sealant coating 
100 mg/ml zobna raztopina, klorheksidinski diacetat Faza 2 tesnilni premaz
Skin and subcutaneous tissues disorders 
FARMACEVTSKA OBLIKA IN VSEBINA dermalna raztopina
• You should not chew gum for at least 24 hours. 
• naj ne žveči žvečilnega gumija vsaj 24 ur;
• Do not floss for 3 days after treatment. 
• naj ne uporabljate zobne nitke tri dni po obravnavi.
Do not chew gum for at least 24 hours. 
Ne žvečite žvečilnega gumija vsaj 24 ur po obravnavi.
Ammonio methacrylate copolymer dispersion, Type B Triethyl citrate 
Faza 2 tesnilni premaz: amonijev metakrilat kopolimer disperzija, tip B trietilcitrat
• You should not brush your teeth for 24 hours after treatment. 
• naj si ne umiva zob prvih 24 ur po zdravljenju.
Each 1 ml of Prevora Dental Solution (Stage 1 chlorhexidine coating) contains chlorhexidine diacetate 100 mg. 
NAVEDBA O AKTIVNI(H) SUBSTANCI(AH) 1 ml Prevora Dental Solution (faza 1 klorheksidinskega premaza) vsebuje 100 mg klorheksidinskega diacetata.
Do not floss your teeth for 3 days following this treatment. 
Ne uporabljate zobne nitke vsaj tri dni po obravnavi.
Figure 2: Tray set up for Stage One Stage 1 chlorhexidine coating and Stage 2 sealant coating treatments. 
En faza 1 klorheksidinski premaz in faza 2 tesnilen premaz.
PACKAGE LEAFLET 
Odmerjanje
Prevora 100 mg/ml Dental Solution 
Prevora 100 mg/ml denalna raztopina
Prevora 100 mg/ml Dental Solution contains: Stage 1 chlorhexidine coating: 
Prevora 100 mg/ml Dental Solution vsebuje: Faza 1 klorheksidinski premaz: klorheksidin diacetat sumatra benzoin etanol
Objectionable, bitter taste when Prevora 100 mg/ml Dental Solution comes into contact with the saliva or oral mucosa 
Bolezni kože in podkožnega tkiva rdečica in/ali začasno zbadajoč občutek na ustni sluznici neprijeten, grenak okus, ko pride Prevora 100 mg/ml Dental Solution v stik s slino ali ustno sluznico
• To avoid eating hard foods (e.g. meat, apples) for at least 4 hours after treatment. 
• naj ne uživa trde hrane (npr. meso, jabolke) vsaj štiri ure po obravnavi.
MA # Read the package leaflet before use. 
Pred uporabo preberite navodila za uporabo.
• You should avoid eating hard foods (e.g. meat, apples) for at least 4 hours after treatment. 
• naj ne uživate trde hrane (npr. meso, jabolke) vsaj štiri ure po obravnavi.
How you are treated with Prevora. 
Kako poteka zdravljenje s Prevora.
• They should avoid eating hard foods (e.g. meat, apples) for at least 4 hours after treatment 
• naj ne uživa trde hrane (npr. meso, jabolke) vsaj štiri ure po obravnavi;
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
DATUM PRVOTNEGA DOVOLJENJA/OBNOVITVE DOVOLJENJA
The active substance is Chlorhexidine diacetate. 
100 mg/ml zobna raztopina Zdravilna učinkovina je klorheksidin diacetat.
Marketing Authorization Holder and Manufacturer 
Vožnja in upravljanje s stroji
This summary was last updated in 07-2011. 
Povzetek je bil nazadnje posodobljen 07-2011.
Entacapone has been authorised in the European Union (EU) as Comtess/Comtan since 1998. 
Entakapon je v Evropski uniji (EU) pod imenom Comtess/Comtan odobren od leta 1998.
The use of combinations of levodopa and carbidopa is well established, having being in use since the mid-1970s. 
Uporaba kombinacij levodope in karbidope je dobro uveljavljena, in sicer od sredine sedemdesetih let prejšnjega stoletja.
Stalevo is used when these fluctuations cannot be treated with the standard combination alone. 
Zdravilo Stalevo se uporablja, kadar teh fluktuacij ni mogoče zdraviti samo s standardno kombinacijo.
Other information about Stalevo 
Druge informacije o zdravilu Stalevo
The full EPAR for Stalevo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Stalevo je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Stalevo to on 17 October 2008. 
Evropska komisija je dovoljenje za promet z zdravilom Stalevo, veljavno po vsej Evropski uniji, odobrila dne 17. oktobra 2008.
What benefit has Stalevo shown during the studies? 
Kakšne koristi je zdravilo Stalevo izkazalo med študijami?
This is a summary of the European public assessment report (EPAR) for Stalevo. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Stalevo.
Stalevo tablets should be taken whole, with or without food. 
Tablete zdravila Stalevo je treba zaužiti cele, s hrano ali brez nje.
What is the risk associated with Stalevo? 
Kakšna tveganja so povezana z zdravilom Stalevo?
Fluctuations happen when the effects of the medication wear off and symptoms re-emerge. 
Te se pojavijo, ko se učinki zdravila porazgubijo in se znova pojavijo simptomi.
Stalevo is used to treat adults with Parkinson's disease. 
Zdravilo Stalevo se uporablja za zdravljenje odraslih s Parkinsonovo boleznijo.
The strength of Stalevo that the patient should use is based on the amount of levodopa they need to control their symptoms. 
Jakost zdravila Stalevo, ki naj jo bolnik jemlje, temelji na količini levodope, ki jo potrebuje za nadzor nad simptomi.
They should not be used in patients with severe liver problems. 
Zdravilo se ne sme uporabljati pri bolnikih s hudimi težavami z jetri.
They are linked with a reduction in the effect of levodopa, when the patient experiences sudden switches between being ‘on' and able to move, and being ‘off' and having difficulty moving about. 
Povezane so z zmanjšanjem učinka levodope, ko bolnik občuti nenadne prehode med stanjem „on“, ko se bolniki lahko premikajo, in stanjem „off“, ko imajo težave z gibanjem.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Stalevo. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Stalevo, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Levodopa is converted into dopamine in the brain. 
Levodopa se v možganih pretvori v dopamin.
The Committee recommended that Stalevo be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Stalevo odobri dovoljenje za promet.
It is available as a range of tablets in seven strengths, containing 50 to 200 mg levodopa and 12.5 to 50 mg carbidopa. 
Na voljo je v obliki tablet v sedmih jakostih, ki vsebujejo od 50 do 200 mg levodope in 12,5 do 50 mg karbidope.
For more information about treatment with Stalevo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Stalevo preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
Having all three substances in the same tablet can lower the number of tablets the patients have to take and help them stick to treatment. 
Ker so vse tri učinkovine v isti tableti, je število tablet, ki jih mora bolnik zaužiti, manjše, kar jim pomaga držati se režima zdravljenja.
All of the tablets contain 200 mg entacapone 
Vse tablete vsebujejo 200 mg entakapona.
The studies showed that Stalevo is bioequivalent to the separate tablets. 
Študije so pokazale, da je zdravilo Stalevo biološko enakovredno tabletam z ločenimi zdravilnimi učinkovinami.
All of the active substances in Stalevo work to restore the levels of dopamine in the parts of the brain that control movement and co-ordination. 
Vse zdravilne učinkovine v zdravilu Stalevo delujejo tako, da ponovno vzpostavijo ravni dopamina v tistih delih možganov, ki nadzirajo gibe in koordinacijo.
Parkinson's disease is a progressive brain disorder that causes shaking, slow movement and muscle stiffness. 
Parkinsonova bolezen je napredujoča bolezen možganov, ki povzroči tresenje, počasno gibanje in okorelost mišic.
The maximum daily dose of Stalevo is 10 tablets, except for the tablets containing 200 mg levodopa and 50 mg carbidopa, for which the maximum daily dose is seven tablets. 
Največji dnevni odmerek zdravila Stalevo je 10 tablet, razen pri tabletah, ki vsebujejo 200 mg levodope in 50 mg karbidope, pri katerih je največji dnevni odmerek sedem tablet.
phaeochromocytoma (a tumour of the adrenal gland); a history of neuroleptic malignant syndrome (a dangerous nervous system disorder usually caused by antipsychotic medicines) or rhabdomyolysis (breakdown of muscle fibres). 
feokromocitomom (tumorjem nadledvične žleze); anamnezo nevroleptičnega malignega sindroma (nevarne bolezni živčnega sistema, ki jo običajno povzročijo antipsihotična zdravila) ali rabdomiolizo (razgradnjo mišičnega tkiva).
The company used some of the data from Comtess/Comtan to support the use of Stalevo and presented data from the published literature for levodopa and carbidopa. 
Družba je v podporo uporabi zdravila Stalevo uporabila nekatere podatke o zdravilu Comtess/Comtan in predstavila podatke iz objavljene literature o levodopi in karbidopi.
Stalevo must not be used together with other medicines that belong to the group ‘monoamine oxidase inhibitors' (a type of antidepressant). 
Zdravilo Stalevo se ne sme uporabljati skupaj z drugimi zdravili, ki spadajo v skupino zaviralcev monoaminooksidaze (vrsta antidepresivov).
The most common side effects with Stalevo (seen in more than 1 patient in 10) are dyskinesia (uncontrollable movements), aggravated Parkinsonism (worsening of Parkinson's disease), nausea (feeling sick) and harmless urine discoloration. 
Najpogostejši neželeni učinki zdravila Stalevo (opaženi pri več kot 1 bolniku od 10) so diskinezija (nekontrolirani gibi), poslabšanje parkinsonizma (Parkinsonove bolezni), slabost in neškodljivo razbarvanje urina.
In patients with Parkinson's disease, the cells in the brain that produce the neurotransmitter dopamine begin to die and the amount of dopamine in the brain decreases. 
Pri bolnikih s Parkinsonovo boleznijo začnejo celice v možganih, ki tvorijo živčni prenašalec dopamin, odmirati, količina dopamina v možganih pa se zmanjša.
Stalevo is a medicine that contains three active substances: levodopa, carbidopa and entacapone. 
Stalevo je zdravilo, ki vsebuje tri zdravilne učinkovine: levodopo, karbidopo in entakapon.
Stalevo should not be used in people who may be hypersensitive (allergic) to levodopa, carbidopa, entacapone or any of the other ingredients. 
Zdravila Stalevo ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) levodopo, karbidopo, entakapon ali katero koli drugo sestavino zdravila.
Both carbidopa and entacapone block some of the enzymes that are involved in the breakdown of levodopa in the body: carbidopa blocks the enzyme dopa decarboxylase, and entacapone blocks the enzyme catechol-O-methyl transferase (COMT). 
Karbidopa in entakapon zavirata nekatere encime, ki sodelujejo pri razgrajevanju levodope v telesu: karbidopa zavira encim dopa dekarboksilazo, entakapon pa zavira encim katehol-O-metiltransferazo (COMT).
Why has Stalevo been approved? 
Zakaj je bilo zdravilo Staleva odobreno?
Each Stalevo tablet contains one complete dose of levodopa, in seven strengths, with corresponding amounts of carbidopa and entacapone to improve its effectiveness. 
Vsaka tableta zdravila Stalevo vsebuje en poln odmerek levodope v sedmih jakostih, za izboljšanje njene učinkovitosti pa še ustrezne količine karbidope in entakapona.
For the full list of all side effects reported with Stalevo, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Stalevo, glejte navodilo za uporabo.
Stalevo must not be used in patients with: severe liver disease; narrow-angle glaucoma (increased pressure within the eye); 
Zdravila Stalevo ne smejo uporabljati bolniki: s hudimi obolenji jeter; glavkomom z zaprtim zakotjem (povečan pritisk v očesu);
Levodopa/carbidopa/entacapone 
Povzetek EPAR za javnost levodopa/karbidopa/entakapon
Stalevo is used in patients who are being treated with a combination of levodopa and an inhibitor of dopa decarboxylase (two standard treatments for Parkinson's disease) but are having ‘fluctuations' towards the end of the period between two doses of their medication. 
Zdravilo Stalevo se uporablja pri bolnikih, ki se zdravijo s kombinacijo levodope in zaviralca dopa dekarboksilaze (dveh običajnih zdravil za Parkinsonovo bolezen), pri katerih pa se proti koncu obdobja med dvema odmerkoma zdravila pojavijo fluktuacije.
What is Stalevo used for? 
Za kaj se zdravilo Stalevo uporablja?
The company carried out ‘bioequivalence' studies to show that taking Stalevo produces the same levels of levodopa, carbidopa and entecapone in the blood as taking separate tablets containing entacapone and the combination of levodopa and carbidopa. 
Izvedla je tudi bioekvivalenčne študije, da bi dokazala, da so ravni levodope, karbidope in entekapona v krvi pri jemanju zdravila Stalevo enake kot pri jemanju zdravilnih učinkovin v ločenih tabletah, od katerih ene vsebujejo entakapon, ter v kombiniranih tabletah, ki vsebujejo levodopo in karbidopo.
The CHMP decided that Stalevo's benefits are greater than its risks for the treatment of patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase inhibitor treatment. 
CHMP je zaključil, da so koristi zdravila Stalevo pri zdravljenju bolnikov s Parkinsonovo boleznijo in motoričnimi fluktuacijami ob koncu odmernega obdobja, ki jih zdravljenje z levodopo/zaviralci dopa dekarboksilaze ne stabilizira, večje od z njim povezanih tveganj.
How does Stalevo work? 
Kako zdravilo Stalevo deluje?
They should be used with caution in patients with mild to moderate problems with their liver or severe problems with their kidneys. 
Bolniki z blagimi do zmerno resnimi težavami z jetri ali hudimi težavami z ledvicami morajo tablete jemati previdno.
How has Stalevo been studied? 
Kako je bilo zdravilo Stalevo raziskano?
How is Stalevo used? 
Kako se zdravilo Stalevo uporablja?
This helps to improve the symptoms of Parkinson's disease, such as stiffness and slowness of movement. 
Posledično ostane levodopa aktivna dlje časa, kar pomaga izboljšati simptome Parkinsonove bolezni, kot sta okorelost mišic in počasnost gibov.
What is Stalevo? 
Kaj je zdravilo Stalevo?
See the Summary of Product Characteristics (also part of the EPAR) for full instructions on how patients should be switched to Stalevo, and on how the dose is adjusted during treatment. 
Za vsa navodila o tem, kako naj bolniki preidejo na jemanje zdravila Stalevo in kako je treba odmerek med zdravljenjem prilagajati, glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
These combinations are not covered in this summary. 
Teh kombinacij ta povzetek ne zajema.
Moreover, the intended use does not require medical supervision. 
Poleg tega namenska uporaba ne zahteva zdravniškega nadzora.
This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU). 
To pomeni, da je kljub pomanjkanju dokazov iz kliničnih preskušanj učinkovitost teh zdravil rastlinskega izvora verjetna in da so na voljo dokazi, da se zdravila na ta način varno uporabljajo vsaj 30 let (od tega vsaj 15 let v EU).
White horehound should only be used in adults and adolescents aged over 12 years. 
Zel navadne črne mete se lahko uporablja le pri odraslih in mladostnikih, starejših od 12 let.
If symptoms of cough persist for longer than one week, patients should consult a qualified healthcare practitioner. 
Če simptomi kašlja trajajo več kot en teden, se morajo bolniki posvetovati z usposobljenim zdravstvenim delavcem.
• in patients with a temporary loss of appetite. 
• pri bolnikih z začasno izgubo teka.
In addition, there were published experimental studies suggesting a number of properties that could plausibly help in patients with mild dyspepsia. 
Poleg tega so bile objavljene poskusne študije, ki kažejo na številne lastnosti, ki verjetno lahko pomagajo bolnikom z blago dispepsijo.
• as an expectorant (a medicine to help bring up phlegm) in patients with cough associated with a cold; 
• kot ekspektorans (zdravilo za lažje izločanje sluzi) pri bolnikih s kašljem, povezanim s prehladom;
At the time of the HMPC assessment, no side effects had been reported with these medicines. 
V času ocenjevanja s strani odbora HMPC niso bili znani nobeni neželeni učinki pri uporabi teh zdravil.
• for treating mild dyspepsia symptoms, such as bloating and flatulence; 
• za lajšanje blagih simptomov dispepsije, kot so napenjanje in vetrovi;
For dyspepsia and loss of appetite, patients are advised to consult healthcare practitioner if symptoms last longer than two weeks. 
Pri dispepsiji in izgubi teka se morajo bolniki posvetovati z zdravstvenim delavcem, če simptomi trajajo več kot dva tedna.
The HMPC conclusions on the use of white horehound medicines in patients with cough, dyspepsia symptoms and loss of appetite are based on their ‘traditional use'. 
Zaključki odbora HMPC o uporabi zdravil iz zeli navadne črne mete pri bolnikih s kašljem, simptomi dispepsije in izgubo teka temeljijo na njihovi „tradicionalni uporabi“.
White horehound EMA/HMPC/446032/2013 
Zel navadne črne mete EMA/HMPC/446032/2013
This summary is not intended to provide practical advice on how to use medicines containing white horehound. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo zel navadne črne mete.
White horehound is the common name for the plant Marrubium vulgare L. The plant is cultivated or gathered to obtain the above-ground parts for medicinal use. 
Zel navadne črne mete je slovensko ime za rastlino Marrubium vulgare L. Rastlina se goji ali nabira za pridobivanje nadzemnih delov za medicinsko uporabo.
Further information on the risks associated with white horehound medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o tveganjih, povezanih z zdravili, ki vsebujejo zel navadne črne mete, vključno z ustreznimi previdnostmi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
The HMPC noted that the bitter substances and essential oils the medicine contains may stimulate appetite and secretions from the lining of the airways. 
Odbor HMPC je ugotovil, da grenke snovi in esencialna olja, ki jih vsebuje zdravilo, lahko spodbudijo tek in izločanje sluzi iz dihalnih poti.
The HMPC concluded that, on the basis of its long-standing use, white horehound can be used in the following ways: 
Odbor HMPC je zaključil, da se zel navadne črne mete glede na njeno dolgotrajno uporabo lahko uporablja na naslednje načine:
Herbal medicines containing white horehound are usually available in a comminuted form for herbal tea, or in solid or liquid forms to be taken by mouth. 
Zdravila rastlinskega izvora, ki vsebujejo zel navadne črne mete, so običajno na voljo v zdrobljeni obliki za zeliščni čaj oziroma v trdni ali tekoči obliki za zaužitje.
In its assessment the HMPC considered the well documented and longstanding use of white horehound in the approved indications. 
Pri svoji oceni je odbor HMPC upošteval dobro dokumentirano in dolgotrajno uporabo zeli navadne črne mete pri odobrenih indikacijah.
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing white horehound. 
Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo zel navadne črne mete.
Information on the use and licensing of white horehound medicines in EU Member States should be obtained from the relevant national authorities. 
Za informacije o uporabi in dovoljenjih za promet z zdravili, ki vsebujejo zel navadne črne mete, v državah članicah EU se obrnite na pristojni nacionalni organ.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of white horehound. 
To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo zeli navadne črne mete.
Any applications for the licensing of medicines containing white horehound have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC. 
Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo zel navadne črne mete, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
Detailed instruction on how to take white horehound medicines and who can use them can be found in the package leaflet that comes with the medicine. 
Podrobna navodila glede tega, kako se uporabljajo zdravila iz zeli navadne črne mete in kdo jih lahko uporablja, najdete v navodilu za uporabo, ki je priloženo zdravilu.
Further information on the HMPC assessment of white horehound medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o oceni zdravil, ki vsebujejo zel navadne črne mete, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.